| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.3M | — | +103.5% |
| SG&A Expense | $6.8M | — | +20.0% |
| Operating Income | -$27.1M | — | -73.1% |
| Net Income | -$26.2M | — | -73.0% |
| EPS (Basic) | -$0.80 | — | -42.9% |
| EPS (Diluted) | -$0.80 | — | -42.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $263.8M | +49.5% | +64.1% |
| Current Assets | $269.1M | +51.4% | +64.6% |
| Total Assets | $276.3M | +49.6% | +60.7% |
| Current Liabilities | $13.1M | +15.8% | +80.7% |
| Long-term Debt | $13.9M | -14.1% | -30.4% |
| Total Liabilities | $32.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$27.1M | — | -63.6% |
| Capital Expenditures | $556K | — | +2216.7% |
| Investing Cash Flow | -$556K | — | -2216.7% |
| Financing Cash Flow | $114.9M | — | +1159.4% |
| Free Cash Flow | -$27.6M | — | -66.7% |
| +0.2% |
| Stockholders' Equity | $243.4M | +61.0% | +75.0% |